First day of trading in warrants of series TO1
Eevia Health Plc ("Eevia" or the "Company") carried out a rights issue of shares and warrants (the “Rights Issue”) in June/July 2024. The first day of trading in warrants of series TO1 (the "Warrants") issued as part of the Rights Issue on Spotlight Stock Market is September 4, 2024. The last day of trading in the Warrants is August 26, 2025. The Warrants will be traded under the short name (ticker) EEVIA TO 1.
Through the Rights Issue, 7,160,396 Warrants of series TO1 have been issued.
Each warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company during the period August 18, 2025, up to and including August 29, 2025. The subscription price for subscription of shares with the support of Warrants of series TO1 will correspond to the volume weighted average price of the Company’s share on Spotlight Stock Market between July 31, 2025, and August 13, 2025, with an applied discount of 25 percent. The subscription price will be minimum SEK 0.60 per share and maximum SEK 2.00 per share.
ADVISERS
Partner Fondkommission is acting as the financial adviser and issuing agent in Sweden for the Rights Issue. OP Bank is the issuing agent in Finland.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc Joel Westerström, Partner Fondkommission
Email: stein.ulve@eeviahealth.com Email: joel.westerstrom@partnerfk.se
Telephone: +358 400 22 5967 Telephone: +46 735 11 68 53
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga, and pine bark, are wild harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.